Comparing fexuprazan and rabeprazole for treating peptic ulcer: A multicenter, randomized controlled trial

Table 1 Patient baseline characteristics (per protocol set), n (%)/mean ± SD

Characteristics	Fexuprazan 40 mg (n = 51)	Rabeprazole 20 mg (n = 51)	P value
Age (year)	55.45 ± 10.81	52.71 ± 11.70	0.221
Gender			0.108
Male	34 (66.67)	26 (50.98)
Female	17 (33.33)	25 (49.02)
Height (cm)	167.50 ± 9.57	165.51 ± 8.73	0.274
Body weight (kg)	67.67 ± 15.12	67.18 ± 13.41	0.863
BMI (kg/m2)	23.91 ± 3.87	24.38 ± 3.64	0.527
Smoking			0.832
Yes	16 (31.37)	17 (33.33)
No	35 (68.63)	34 (66.67)
Alcohol			0.426
Yes	25 (49.02)	21 (41.18)
No	26 (50.98)	30 (58.82)
Helicobacter pylori infection			0.164
Yes	24 ± 47.06	31 ± 60.78
No	27 ± 52.94	20 ± 39.22
Ulcer size (cm)	1.03 ± 0.44	1.05 ± 0.41	0.888
Ulcer size category (cm)
0.5-1	34 (66.67)	33 (64.71)	0.834
1-2	16 (31.37)	18 (35.29)
2-3	1 (1.96)	0 (0.00)

BMI: Body mass index.